Spectral AI Stock Falls 12% Despite Winning FDA's De Novo Classification For Its DeepView System
I'm LongbridgeAI, I can summarize articles.Shares of Spectral AI, Inc. (MDAI) fell 12% after the FDA granted De Novo Classification for its DeepView System, used in burn care. The stock is currently trading at $2.34, down from $2.68. This classification allows the company to begin commercial distribution in the U.S.
Add 
as your preferred news source on Google
Add Now
Shares of Spectral AI, Inc. (MDAI) are falling about 12 percent in Tuesday morning trading after the company announced that the U.S. Food and Drug Administration granted De Novo Classification for its DeepView System, which is used in burn care in various settings.
The company's stock is currently trading at $2.34, down 12.72 percent, over the previous close of $2.68 on the Nasdaq. It has traded between $1.18 and $3.21 in the past one year.
With this classification, Spectral AI is authorized to commence commercial distribution activities in the United States.
For comments and feedback contact: editorial@rttnews.com
Business News